ALK and neoplasm: In 2930 patients with 11 tumor types treated with immune checkpoint inhibitors, the mutation of <i>ALK</i> indicated favorable overall survival (hazard ratio = 0.69; 95% confidence interval, 0.57-0.83; <i>p</i> < 0.001).